CA2572819A1 — Methylidene-d-xylopyranosyl-substituted and oxo-d-xylopyranosyl-substituted phenyls, medicaments containing these compounds, their use and method for the production thereof
Assigned to Boehringer Ingelheim International GmbH · Expires 2006-01-26 · 20y expired
What this patent protects
D-xylopyranosyl-substituted phenyls of general formula (I), in which radicals R1 to R5, X, Z as well as R7a, R7b and R7c are defined as in Claim 1, exhibit an inhibiting effect upon the sodium-dependent glucose-cotransporter SGLT. The invention also relates to medicaments for tre…
USPTO Abstract
D-xylopyranosyl-substituted phenyls of general formula (I), in which radicals R1 to R5, X, Z as well as R7a, R7b and R7c are defined as in Claim 1, exhibit an inhibiting effect upon the sodium-dependent glucose-cotransporter SGLT. The invention also relates to medicaments for treating metabolic diseases.
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.